Health Care [ 3/12 ] | Pharmaceuticals [ 19/73 ]
NYSE | Common Stock
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).
It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD.
The company was incorporated in 2019 and is headquartered in Mountain View, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 25 | -0.65 Decreased by -8.33% | -0.60 Decreased by -8.33% |
| May 15, 25 | -0.56 Increased by +26.32% | -0.57 Increased by +1.75% |
| Mar 20, 25 | -0.52 Increased by +93.31% | -0.55 Increased by +5.45% |
| Nov 13, 24 | -0.62 | -0.56 Decreased by -10.71% |
| Aug 13, 24 | -0.60 | -0.53 Decreased by -13.21% |
| May 14, 24 | -0.76 | -0.46 Decreased by -65.22% |
| Mar 21, 24 | -7.77 | -1.67 Decreased by -365.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -17.71 M Decreased by -10.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -15.17 M Decreased by -13.06% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 394.00 K Increased by +5.91% | -15.20 M Decreased by -35.52% | Decreased by -3.86 K% Decreased by -27.95% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -16.78 M Decreased by -83.60% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -16.03 M Decreased by -85.04% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -13.42 M Decreased by -84.20% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 372.00 K Increased by +N/A% | -11.22 M Decreased by -46.59% | Decreased by -3.02 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 - | -9.14 M - | Decreased by N/A% - |